Radioactive Iodine Ablation Decrease Recurrences in Papillary Thyroid Microcarcinoma with Lateral Lymph Node Metastasis in Chinese Patients

Overview

Journal World J Surg

Publisher Wiley

Specialty General Surgery

Date 2017 Jul 26

PMID 28741199

Citations 5

Authors

Shuai Xue

Peisong Wang

Jia Liu

Guang Chen

Affiliations

Soon will be listed here.

Abstract

Introduction: We aimed to carry out a retrospective study from a single institution to determine whether radioactive iodine (RAI) ablation decreases the risk of recurrence of papillary thyroid microcarcinoma (PTMC) patients that presented with lateral lymph node metastasis (LLNM).

Methods: We retrospectively analyzed a total of 6361 consecutive PTMC patients who initially underwent surgery for the treatment of thyroid carcinoma at the First Hospital of Jilin University, between January 2005 and February 2015. Altogether, 137 patients with PTMC with LLNM have been enrolled in our study.

Results: The disease-free survival period was significantly shorter for the RAI (-) patients than for the RAI (+) patients (p = 0.0074 by the log-rank test). The disease-free survival rates at 5 and 10 years were 93.02 and 87.5%, respectively, in the RAI (-) group and 100 and 96.81%, respectively, in the RAI (+) group. CLNM ratio and LLNM ratio were factors identified for multivariate analysis by Cox's proportional hazards method yielding risk ratios of 7.281 [CI 1.804-17.554; p = 0.010] and 1.157 [CI 1.0125-9.381; p = 0.048] in the RAI (-) group.

Conclusion: Taken together, RAI may be beneficial for PTMC with LLNM, especially when CLNM ratio or LLNM ratio was greater than 0.5.

Citing Articles

Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis.

Zhao M, Shi X, Zhang J, Deng S, Zhou Y, Wen R Comput Math Methods Med. 2022; 2022:8028846.

PMID: 36110571 PMC: 9470344. DOI: 10.1155/2022/8028846.

A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis.

Rui Z, Liu Y, Zheng W, Wang X, Meng Z, Tan J Clin Exp Med. 2021; 21(2):277-286.

PMID: 33386568 DOI: 10.1007/s10238-020-00675-8.

Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Braf Mutation: A Single Center Study of 1,207 Chinese Patients.

Xue S, Zhang L, Wang P, Liu J, Yin Y, Jin M Front Endocrinol (Lausanne). 2019; 10:407.

PMID: 31297091 PMC: 6607364. DOI: 10.3389/fendo.2019.00407.

The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy?.

Shen G, Kou Y, Liu B, Huang R, Kuang A Nucl Med Commun. 2018; 40(1):8-13.

PMID: 30312216 PMC: 6282664. DOI: 10.1097/MNM.0000000000000930.

A retrospective study of the clinical features in papillary thyroid microcarcinoma depending on age.

Wang X, Tan J, Zheng W, Li N Nucl Med Commun. 2018; 39(8):713-719.

PMID: 29762261 PMC: 6075886. DOI: 10.1097/MNM.0000000000000859.

References

Siddiqui S, White M, Antic T, Grogan R, Angelos P, Kaplan E . Clinical and Pathologic Predictors of Lymph Node Metastasis and Recurrence in Papillary Thyroid Microcarcinoma. Thyroid. 2016; 26(6):807-15. DOI: 10.1089/thy.2015.0429. View

Zhang L, Wei W, Ji Q, Zhu Y, Wang Z, Wang Y . Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012; 97(4):1250-7. DOI: 10.1210/jc.2011-1546. View

Choi S, Cho J, Moon J, Son Y . Metastatic Lymph Node Ratio of Central Neck Compartment Has Predictive Values for Locoregional Recurrence in Papillary Thyroid Microcarcinoma. Clin Exp Otorhinolaryngol. 2016; 9(1):75-9. PMC: 4792245. DOI: 10.21053/ceo.2016.9.1.75. View

Baudin E, Travagli J, Ropers J, Mancusi F, Caillou B, Cailleux A . Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998; 83(3):553-9. DOI: 10.1002/(sici)1097-0142(19980801)83:3<553::aid-cncr25>3.0.co;2-u. View

Kim T, Hong S, Kim J, Kim W, Gong G, Ryu J . Prognostic parameters for recurrence of papillary thyroid microcarcinoma. BMC Cancer. 2008; 8:296. PMC: 2576338. DOI: 10.1186/1471-2407-8-296. View

Davies L, Welch H . Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295(18):2164-7. DOI: 10.1001/jama.295.18.2164. View

Lombardi C, Bellantone R, De Crea C, Paladino N, Fadda G, Salvatori M . Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area. World J Surg. 2010; 34(6):1214-21. DOI: 10.1007/s00268-009-0375-x. View

Creach K, Siegel B, Nussenbaum B, Grigsby P . Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma. ISRN Endocrinol. 2012; 2012:816386. PMC: 3313572. DOI: 10.5402/2012/816386. View

Wang T, Goffredo P, Sosa J, Roman S . Papillary thyroid microcarcinoma: an over-treated malignancy?. World J Surg. 2014; 38(9):2297-303. DOI: 10.1007/s00268-014-2602-3. View

10.

Mehanna H, Al-Maqbili T, Carter B, Martin E, Campain N, Watkinson J . Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J Clin Endocrinol Metab. 2014; 99(8):2834-43. DOI: 10.1210/jc.2013-2118. View

11.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

12.

Chen Y, Sadow P, Suh H, Lee K, Choi J, Suh Y . BRAF(V600E) Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. Thyroid. 2015; 26(2):248-55. DOI: 10.1089/thy.2015.0391. View

13.

Pisanu A, Saba A, Podda M, Reccia I, Uccheddu A . Nodal metastasis and recurrence in papillary thyroid microcarcinoma. Endocrine. 2014; 48(2):575-81. DOI: 10.1007/s12020-014-0350-7. View

14.

Rosario P, Calsolari M . Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2012; 23(5):617-9. DOI: 10.1089/thy.2012.0050. View

15.

Hu G, Zhu W, Yang W, Wang H, Shen L, Zhang H . The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis. World J Surg. 2015; 40(1):100-9. DOI: 10.1007/s00268-015-3346-4. View

16.

Patel S, Goldfarb M . Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. J Surg Oncol. 2012; 107(6):665-72. DOI: 10.1002/jso.23295. View

17.

Pisanu A, Reccia I, Nardello O, Uccheddu A . Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg. 2009; 33(3):460-8. DOI: 10.1007/s00268-008-9870-8. View

18.

Pyo J, Sohn J, Kang G . Detection of Tumor Multifocality Is Important for Prediction of Tumor Recurrence in Papillary Thyroid Microcarcinoma: A Retrospective Study and Meta-Analysis. J Pathol Transl Med. 2016; 50(4):278-86. PMC: 4963970. DOI: 10.4132/jptm.2016.03.29. View

19.

Lang B, Wong I, Wong K, Cowling B, Wan K . Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery. 2012; 151(6):844-50. DOI: 10.1016/j.surg.2011.12.019. View

20.

Al-Qahtani K, Al Asiri M, Tunio M, Aljohani N, Bayoumi Y, Fatani H . Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected]. J Otolaryngol Head Neck Surg. 2015; 44:51. PMC: 4666037. DOI: 10.1186/s40463-015-0108-0. View